The role of galectin-3 in the diagnosis and control of the effectiveness of pharmacotherapy of chronic heart failure


如何引用文章

全文:

详细

Relevance. At present, it is urgent to develop new biomarkers that can serve as a tool for early diagnosis of the disease in order to select pharmacotherapy and further monitor its effectiveness. The goal is to evaluate the clinical value of the definition of galectin-3 in patients with chronic heart failure (CHF). Materials and methods. The study included 53 patients (31 women, 22 men) with CHF II-III functional class (FC) of the New York Heart Association (NYHA). The mean age of the patients was 71 years (95% confidence interval 68.99-74.37). A group of patients with NYHA FCh II CHF made up 14 people, a group of patients with NYHA-39 CHF III FC. The median of the initial level of the N-terminal brain natriuretic peptide (NT-proBNP) was 65.7 pmol/L, the median of the initial level of galectin-3 - 8.37 pmol/l. Results. The relationship of increased level of galectin-3 with reduced ejection fraction,% (r=-0.26, p=0.04), increased creatinine level (r=0.26, p=0.04) and increased level of NT-proBNP plasma (r=0.3, p=0.02). With other clinical indicators, such as systolic and diastolic blood pressure, heart rate, body mass index, 6-minute walk test, left ventricular mass index, glucose level, total cholesterol, glomerular filtration rate, no statistically significant association was found. A moderate correlation was obtained between the levels of NT-proBNP and galectin-3 plasma (r=0.3, p=0.02). Reduction in the level of galectin-3 after the treatment was detected in 84.3% of patients. The conclusion. Galectin-3 can serve as an additional diagnostic biomarker of CHF.

作者简介

K. Giamdzhian

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Email: karina.gyamdjyan@gmail.com
аспирант каф. клинической фармакологии и пропедевтики внутренних болезней Ф 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

V. Kukes

I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

акад. РАН, д-р мед. наук, проф., зав. каф. клинической фармакологии и пропедевтики внутренних болезней 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

参考

  1. Lok D.J, Van Der Meer P, de la Porte P.W. et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010; 99 (5): 323-8.
  2. De Boer R.A, Lok D.J.A, Jaarsma T. et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011; 43 (1): 60-8.
  3. De Boer R.A, van der Velde A, Mueller C. et al. Galectin-3: A Modifiable Risk Factor in Heart Failure. Cardiovasc Drugs Ther 2014; 28: 237-46.
  4. Liu Y.H, d’Ambrosio M, Liao T.D. et al. N-Acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growthregulatory lectin. Am J Physiol Heart Circ Physiol 2009; 296: H404-12.
  5. Kim H. et al. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int 2007; 31 (7): 655-62.
  6. Tang W.H, Shrestha K, Shao Z. et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011; 108: 385-90.
  7. Ueland T, Aukrust P, Broch K. et al. Galectin-3 in heart failure: high levels are associated with all-cause mortality. Int J Cardiol 2011; 150: 361-4.
  8. Lopez-Andrès N, Rossignol P, Iraqi W et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012; 14: 74-81.
  9. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013; 14 (7): 379-472
  10. Mueller T et al. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 2005; 91: 606-12.
  11. Anand I.S. et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-HeFT). Circulation 2003; 107: 1278-83.
  12. Felker G.M, Fiuzat M, Shaw L.K. et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 2012; 5 (1): 72-8.
  13. Motiwala S. et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail 2013; 15: 1157-63.
  14. Anand I.S. et al. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 2013; 15: 511-8.
  15. Van Kimmenade R.R. et al. Utility of amino-terminal probrain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48: 1217-24.
  16. Batlle M. et al. Data on clinical characteristics of a heart failure patients’ cohort with reduced ejection fraction and analysis of the circulating values of five different heart failure biomarkers; high sensitivity troponin T, galectin-3, C-terminal propeptide of type I procollagen, soluble AXL and BNP. Data Brief 2016; 9: 876-82.
  17. Januzzi J.L. et al. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. Am J Cardiol 2005; 95: 948-54.
  18. Calvier L. et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Atheroscler Thromb Vasc Biol 2013; 33 (1): 67-75.
  19. Deveci O.S. et al. A novel BioTarget in Treatment of Heart Failure: Changes in Serum Galectin-3 Levels after Spironolactone Therapy. J Hypertens 2015; 4: 1.
  20. McCullough P.A.et al. Galectn-3: A novel Blood Test for the Evaluation and Management of Patients with Heart Failure. Rev Cardiovasc Med 2011; 12 (4): 200-10.

版权所有 © Eco-Vector, 2017

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。

##common.cookie##